Cite
HARVARD Citation
Bachelot, T. et al. (2019). Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology. pp. 766-773. [Online].